Re-exposure to the hypobaric hypoxic brain injury of high altitude: plasma S100B levels and the possible effect of acclimatisation on blood-brain barrier dysfunction.

Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100959175 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1590-3478 (Electronic) Linking ISSN: 15901874 NLM ISO Abbreviation: Neurol Sci Subsets: MEDLINE

Original Publication: Milano, Italy : Springer-Verlag Italia, c2000-

Altitude*; Blood-Brain Barrier/*metabolism ; Hypoxia/*blood ; S100 Calcium Binding Protein beta Subunit/*blood; Adult ; Altitude Sickness/blood ; Altitude Sickness/prevention & control ; Blood-Brain Barrier/drug effects ; Dexamethasone/therapeutic use ; Female ; Humans ; Hypoxia/drug therapy ; Hypoxia, Brain ; Japan ; Male ; Middle Aged ; Neuroprotective Agents/therapeutic use ; Oxygen/blood ; Time Factors ; Young Adult

Hypobaric hypoxic brain injury results in elevated peripheral S100B levels which may relate to blood-brain barrier (BBB) dysfunction. A period of acclimatisation or dexamethasone prevents altitude-related illnesses and this may involve attenuation of BBB compromise. We hypothesised that both treatments would diminish the S100B response (a measure of BBB dysfunction) on re-ascent to the hypobaric hypoxia of high altitude, in comparison to an identical ascent completed 48 h earlier by the same group. Twelve healthy volunteers, six of which were prescribed dexamethasone, ascended Mt Fuji (summit 3700 m) and serial plasma S100B levels measured. The S100B values reduced from a baseline 0.183 µg/l (95 % CI 0.083-0.283) to 0.145 µg/l (95 % CI 0.088-0.202) at high altitude for the dexamethasone group (n = 6) and from 0.147 µg/l (95 % CI 0.022-0.272) to 0.133 µg/l (95 % CI 0.085-0.182) for the non-treated group (n = 6) [not statistically significant (p = 0.43 and p = 0.82) for the treated and non-treated groups respectively]. [These results contrasted with the statistically significant increase during the first ascent, S100B increasing from 0.108 µg/l (95 % CI 0.092-0.125) to 0.216 µg/l (95 % CI 0.165-0.267) at high altitude]. In conclusion, an increase in plasma S100B was not observed in the second ascent and this may relate to the effect of acclimatisation (or hypoxic pre-conditioning) on the BBB. An exercise stimulated elevation of plasma S100B levels was also not observed during the second ascent. The small sample size and wide confidence intervals, however, precludes any statistically significant conclusions and a larger study would be required to confirm these findings.

Front Biosci. 2002 May 1;7:d1356-68. (PMID: 11991838)
Brain Res. 2002 Jun 14;940(1-2):102-4. (PMID: 12020881)
J Neurosci. 2002 Aug 1;22(15):6401-7. (PMID: 12151519)
High Alt Med Biol. 2002 Summer;3(2):195-204. (PMID: 12162863)
Restor Neurol Neurosci. 2003;21(3-4):109-21. (PMID: 14530574)
Ann Biol Clin (Paris). 1999 May;57(3):261-72. (PMID: 10377476)
J Neurotrauma. 2005 Jun;22(6):645-55. (PMID: 15941374)
Neurobiol Dis. 2006 Jan;21(1):18-28. (PMID: 16040250)
Cell Mol Neurobiol. 2006 Feb;26(1):81-6. (PMID: 16633903)
Sleep Med. 2006 Aug;7(5):431-5. (PMID: 16750933)
J Neurotrauma. 2006 Aug;23(8):1185-200. (PMID: 16928177)
Respir Med. 2007 Mar;101(3):587-94. (PMID: 16890420)
J Cereb Blood Flow Metab. 2007 May;27(5):1064-71. (PMID: 17024110)
Biochem Biophys Res Commun. 2008 Jul 18;372(1):243-8. (PMID: 18485896)
Lancet Neurol. 2009 Feb;8(2):175-91. (PMID: 19161909)
Neurosci Lett. 2009 Mar 13;452(2):114-8. (PMID: 19135131)
Biochim Biophys Acta. 2009 Jun;1793(6):1008-22. (PMID: 19110011)
High Alt Med Biol. 2009 Fall;10(3):221-32. (PMID: 19775211)
J Neurotrauma. 2009 Sep;26(9):1497-1507. (PMID: 19257803)
Am J Physiol Heart Circ Physiol. 2010 Jan;298(1):H179-88. (PMID: 19855054)
Brain Res. 2010 Apr 14;1325:1-9. (PMID: 20153736)
High Alt Med Biol. 2010 Spring;11(1):31-8. (PMID: 20367486)
Prog Cardiovasc Dis. 2010 May-Jun;52(6):467-84. (PMID: 20417340)
ASN Neuro. 2011;3(3):e00062. (PMID: 21722095)
J Neurochem. 2012 Mar;120(5):644-59. (PMID: 22145907)
Neurosci Bull. 2012 Jun;28(3):316-20. (PMID: 22622832)
Eur J Appl Physiol. 2012 Sep;112(9):3287-94. (PMID: 22252248)
Sports Med. 2014 Mar;44(3):369-85. (PMID: 24194479)
J Neurochem. 2014 Apr;129(1):120-9. (PMID: 24251624)
PLoS One. 2014;9(3):e92191. (PMID: 24658407)
J Appl Physiol (1985). 2014 Apr 1;116(7):724-9. (PMID: 24371013)
Int J Cardiol. 2014 May 1;173(2):133-8. (PMID: 24679688)
High Alt Med Biol. 2014 Jun;15(2):133-40. (PMID: 24971767)
Neurol Res. 2014 Sep;36(9):779-85. (PMID: 24620985)
Mediators Inflamm. 2015;2015:632592. (PMID: 26273140)
Eur J Neurol. 2015 Oct;22(10):1363-9. (PMID: 25040466)
Eur J Pharmacol. 2001 Jan 12;411(3):231-43. (PMID: 11164380)
J Neurol Sci. 2001 Mar 1;184(2):101-22. (PMID: 11239944)
J Appl Physiol (1985). 2001 Apr;90(4):1431-40. (PMID: 11247944)

Keywords: Acclimatisation; Blood–brain barrier; Dexamethasone; High altitude; Hypoxia; S100B

0 (Neuroprotective Agents)
0 (S100 Calcium Binding Protein beta Subunit)
0 (S100B protein, human)
7S5I7G3JQL (Dexamethasone)
S88TT14065 (Oxygen)

Date Created: 20160301 Date Completed: 20161222 Latest Revision: 20181113

20250114

PMC4819780

10.1007/s10072-016-2521-1

26924650